Chronic lymphoid leukemia cells are highly sensitive to the combination of prednisolone and daunorubicin, but much less to doxorubicin or epirubicin

Experimental Hematology

Volumn 38, Issue 12, 2010, Pages 1219-1230

  Skribek, Henriette ^a   Otvos, Rita ^a   Flaberg, Emilie ^a   Nagy, Noemi ^a   Markasz, Laszlo ^a   Eksborg, Staffan ^b   Masszi, Tamas ^c   Kozma, Andras ^c   Adam, Emma ^c   Miseta, Attila ^d   Klein, Eva ^a   Szekely, Laszlo ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c Szent Laszlo Hospital   (Hungary)

^d UNIVERSITY OF PÉCS   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; BLEOMYCIN; BORTEZOMIB; CARBOPLATIN; CHLORAMBUCIL; CLADRIBINE; CYTARABINE; DACTINOMYCIN; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; FLUDARABINE PHOSPHATE; FLUOROURACIL; GEMCITABINE; HYDROXYUREA; MERCAPTOPURINE; METHOTREXATE; MITOMYCIN; NAVELBINE; OXALIPLATIN; PACLITAXEL; PRECORTALON AQUOSUM; PREDNISOLONE; TOPOTECAN; UNCLASSIFIED DRUG; VINBLASTINE SULFATE; VINCRISTINE;

ARTICLE; AUTOMATION; CANCER RESISTANCE; CELL ASSAY; CELL HETEROGENEITY; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG POTENCY; DRUG SENSITIVITY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE; CLUSTER ANALYSIS; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PREDNISOLONE;

EID: 78549233335     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2010.09.001     Document Type: Article

References (39)

1. Pekarsky Y., Zanesi N., Aqeilan R.I., Croce C.M. Animal models for chronic lymphocytic leukemia. J Cell Biochem 2007, 100:1109-1118.
2. Boelens J., Lust S., Vanhoecke B., Offner F. Chronic lymphocytic leukaemia. Anticancer Res 2009, 29:605-615.
3. Klein U., Tu Y., Stolovitzky G.A., et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001, 194:1625-1638.
4. Rai K.R., Sawitsky A., Cronkite E.P., Chanana A.D., Levy R.N., Pasternack B.S. Clinical staging of chronic lymphocytic leukemia. Blood 1975, 46:219-234.
5. Binet J.L., Lepoprier M., Dighiero G., et al. A clinical staging system for chronic lymphocytic leukemia: prognostic significance. Cancer 1977, 40:855-864.
6. Zenz T., Mohr J., Edelmann J., et al. Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway. Leuk Lymphoma 2009, 50:510-513.
7. Kay N.E., O'Brien S.M., Pettitt A.R., Stilgenbauer S. The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia. Leukemia 2007, 21:1885-1891.
8. Yee K.W., O'Brien S.M. Chronic lymphocytic leukemia: diagnosis and treatment. Mayo Clin Proc 2006, 81:1105-1129.
9. Nabhan C., Coutré S., Hillmen P. Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime?. Br J Haematol 2007, 136:379-392.
10. Klein A., Miera O., Bauer O., Golfier S., Schriever F. Chemosensitivity of B cell chronic lymphocytic leukemia and correlated expression of proteins regulating apoptosis, cell cycle and DNA repair. Leukemia 2000, 14:40-46.
11. Ricci F., Tedeschi A., Morra E., Montillo M. Fludarabine in the treatment of chronic lymphocytic leukemia: a review. Ther Clin Risk Manag 2009, 5:187-207.
12. Gribben J.G., Hallek M. Rediscovering alemtuzumab: current and emerging therapeutic roles. Br J Haematol 2009, 144:818-831.
13. Faderl S., Ferrajoli A., Frankfurt O., Pettitt A. Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy. Leukemia 2009, 23:457-466.
14. Bosch F., Ferrer A., Villamor N., et al. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. Clin Cancer Res 2008, 14:155-161.
15. Boyiadzis M., Foon K.A., Pavletic S. Hematopoietic stem cell transplantation for chronic lymphocytic leukemia: potential cure for an incurable disease. Expert Opin Biol Ther 2007, 7:1789-1797.
16. Tam C.S., Khouri I. The role of stem cell transplantation in the management of chronic lymphocytic leukaemia. Hematol Oncol 2009, 27:53-60.
17. Silva K.L., Vasconcellos D.V., Castro E.D., Vasconcelos F.C., Bigni R., Maia R.C. Bisphosphonates induce apoptosis in CLL cells independently of MDR phenotype. Cancer Chemother Pharmacol 2008, 62:165-171.
18. Merkel O., Heyder C., Asslaber D., et al. Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del17p13. J Mol Med 2008, 86:541-552.
19. Jensen M., Engert A., Weissinger F., et al. Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia. Invest New Drugs 2008, 26:139-149.
20. Ferrajoli A., Lee B.N., Schlette E.J., et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008, 111:5291-5297.
21. Markasz L., Kis L.L., Stuber G., et al. Hodgkin-lymphoma-derived cells show high sensitivity to dactinomycin and paclitaxel. Leuk Lymphoma 2007, 48:1835-1845.
22. Markasz L., Skribek H., Uhlin M., et al. Effect of frequently used chemotherapeutic drugs on cytotoxic activity of human cytotoxic T-lymphocytes. J Immunother 2008, 31:283-293.
23. Markasz L., Stuber G., Flaberg E., et al. Cytotoxic drug sensitivity of Epstein-Barr virus transformed lymphoblastoid B-cells. BMC Cancer 2006, 6:265.
24. Markasz L., Stuber G., Vanherberghen B., et al. Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells. Mol Cancer Ther 2007, 6:644-654.
25. Saldanha A.J. Java Treeview-extensible visualization of microarray data. Bioinformatics 2004, 20:3246-3248.
26. Zupo S., Isnardi L., Megna M., et al. CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM antibodies and propensity to apoptosis. Blood 1996, 88:1365-1374.
27. Yu Z., Sun B., Kantarjian H.M., Keating M.J., Amin H.M., Sun X. Protein expression profiling of cytokines and cytokine receptors on purified chronic lymphocytic leukemia cells from patients with favourable prognostic indicators. Leuk Lymphoma 2008, 49:751-756.
28. Bandobashi K., Liu A., Nagy N., et al. EBV infection induces expression of the transcription factors ATF-2/c-Jun in B lymphocytes but not in B-CLL cells. Virus Genes 2005, 30:323-330.
29. Maeda A., Bandobashi K., Nagy N., et al. Epstein-barr virus can infect B-chronic lymphocytic leukemia cells but it does not orchestrate the cell cycle regulatory proteins. J Hum Virol 2001, 4:227-237.
30. Runarsson G., Liu A., Mahshid Y., et al. Leukotriene B4 plays a pivotal role in CD40-dependent activation of chronic B lymphocytic leukemia cells. Blood 2005, 105:1274-1279.
31. Eichhorst B.F., Busch R., Stilgenbauer S., et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009, 114:3382-3391.
32. Bernabei P.A., Landini I., Bartolozzi B., et al. Activity of vinorelbine on B-chronic lymphocytic leukemia cells in vitro. Adv Exp Med Biol 1999, 457:473-476.
33. Uckun F.M., Morar S., Qazi S. Vinorelbine-based salvage chemotherapy for therapy-refractory aggressive leukaemias. Br J Haematol 2006, 135:500-508.
34. Vilpo J.A., Koski T., Vilpo L.M. Selective toxicity of vincristine against chronic lymphocytic leukemia cells in vitro. Eur J Haematol 2000, 65:370-378.
35. Markasz L., Vanherberghen B., Flaberg E., et al. NK cell-mediated lysis is essential to kill Epstein-Barr virus transformed lymphoblastoid B cells when using rituximab. Biomed Pharmacother 2009, 63:413-420.
36. Cheson B.D., Rummel M.J. Bendamustine: rebirth of an old drug. J Clin Oncol 2009, 27:1492-1501.
37. Kasteng F., Sobocki P., Svedman C., Lundkvist J. Economic evaluations of leukemia: a review of the literature. Int J Technol Assess Health Care 2007, 23:43-53.
38. Tsimberidou A.M., Kantarjian H.M., Cortes J., et al. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer 2003, 97:1711-1720.
39. Dabaja B.S., O'Brien S.M., Kantarjian H.M., et al. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome. Leuk Lymphoma 2001, 42:329-337.